Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

13 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03126760 (ClinicalTrials.gov)	May 22, 2017	4/4/2017	Pilot Study to Assess the Efficacy & Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis	A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis	Relapsing, Remitting Multiple Sclerosis	Drug: Repository Corticotropin Injection;Drug: Placebo	Mallinckrodt	NULL	Terminated	18 Years	N/A	All	35	Phase 4	United States
2	NCT03021317 (ClinicalTrials.gov)	February 2017	12/1/2017	Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses	Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses	Multiple Sclerosis	Drug: ACTHar	University of Chicago	NULL	Not yet recruiting	18 Years	N/A	All	18	Phase 4	NULL
3	NCT02446886 (ClinicalTrials.gov)	June 2016	7/5/2015	Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS	Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS	Multiple Sclerosis	Drug: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)	Weill Medical College of Cornell University	Mallinckrodt	Completed	18 Years	N/A	All	15	Phase 4	United States
4	NCT02315872 (ClinicalTrials.gov)	May 22, 2015	9/12/2014	ACTH for Fatigue in Multiple Sclerosis Patients	The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis.	Multiple Sclerosis, Relapsing-Remitting	Drug: ACTH;Drug: Placebo	Providence Health & Services	Mallinckrodt	Completed	18 Years	65 Years	All	8	Phase 3	United States
5	NCT02258217 (ClinicalTrials.gov)	June 2014	2/10/2014	Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)	Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)	Relapsing Remitting Multiple Sclerosis	Drug: Acthar	OhioHealth	NULL	Completed	18 Years	N/A	All	30	N/A	United States
6	NCT01950234 (ClinicalTrials.gov)	October 2013	30/8/2013	ACTH in Progressive Forms of MS	Treatment of Progressive Forms of Multiple Sclerosis With Pulsed ACTH (Acthar Gel)	Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis;Progressive Relapsing Multiple Sclerosis	Drug: ACTH;Drug: Placebo	University of Minnesota	Mallinckrodt	Active, not recruiting	18 Years	N/A	All	100	Phase 2	United States
7	NCT01906684 (ClinicalTrials.gov)	August 2013	19/7/2013	Comprehensive Analysis of Relapse in Multiple Sclerosis	Comprehensive Analysis of Relapse in Multiple Sclerosis	Multiple Sclerosis	Drug: Acthar Gel	Tanner Foundation for Multiple Sclerosis	Questcor Pharmaceuticals, Inc.;Auburn University MRI Research Center;iReportoire Inc	Not yet recruiting	19 Years	65 Years	Both	20	N/A	United States
8	NCT02290444 (ClinicalTrials.gov)	August 2013	23/10/2014	Effects of Acthar on Recovery From Cognitive Relapses in MS	Effects of Adrenocorticotropic Hormone (ACTHAR Gel) on Recovery From Cognitive Relapses in Multiple Sclerosis	Multiple Sclerosis	Drug: Adrenocorticotropic Hormone	State University of New York at Buffalo	NULL	Completed	18 Years	65 Years	All	64	Phase 3	United States
9	NCT01900093 (ClinicalTrials.gov)	July 2013	11/7/2013	Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses	An Open-Label Prospective Proof-Of-Concept Trial to Evaluate the Response to Acthar Gel Therapy in Patients With Multiple Sclerosis (MS) Relapses Who Have Failed To Make an Adequate Recovery After Treatment With High-Dose Intravenous Methylprednisolone	Multiple Sclerosis	Drug: Acthar Gel	Aaron Miller	Mallinckrodt	Recruiting	18 Years	65 Years	All	10	N/A	United States
10	NCT01838174 (ClinicalTrials.gov)	May 2013	18/4/2013	A Trial of Neuroprotection With ACTH in Acute Optic Neuritis	A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis	Multiple Sclerosis	Drug: ACTHAR Gel (ACTH);Drug: IV methylprednisolone (steroids)	University of Colorado, Denver	Mallinckrodt;University of Pennsylvania	Terminated	18 Years	55 Years	All	100	Phase 4	United States
11	NCT01888354 (ClinicalTrials.gov)	April 2013	16/5/2013	Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations	Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ) Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations	Multiple Sclerosis (MS)	Drug: H.P. Acthar Gel (repository corticotropin injection)	The University of Texas Health Science Center, Houston	NULL	Completed	18 Years	55 Years	Both	25	Phase 4	United States
12	NCT01049451 (ClinicalTrials.gov)	November 2009	13/1/2010	Pulse ACTH vs. MP for MS	Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif)	Multiple Sclerosis	Drug: ACTH;Drug: Methylprednisolone	University of Southern California	NULL	Completed	18 Years	65 Years	All	23	Phase 1	United States
13	NCT00854750 (ClinicalTrials.gov)	May 2009	27/2/2009	Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis	Modeling and Treating the Pathophysiology of Demyelination in Multiple Sclerosis	Multiple Sclerosis	Drug: ACTHAR	Elliot Frohman	Questcor Pharmaceuticals, Inc.	Terminated	18 Years	65 Years	Both	1	Phase 4	United States